AlloVir (ALVR) Competitors $4.76 +0.31 (+6.97%) As of 10/13/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ALVR vs. CTOR, PEPG, THTX, ANRO, CGEN, CCCC, ACOG, NVCT, IXHL, and GLSIShould you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Citius Oncology (CTOR), PepGen (PEPG), Theratechnologies (THTX), Alto Neuroscience (ANRO), Compugen (CGEN), C4 Therapeutics (CCCC), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Incannex Healthcare (IXHL), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. AlloVir vs. Its Competitors Citius Oncology PepGen Theratechnologies Alto Neuroscience Compugen C4 Therapeutics Alpha Cognition Nuvectis Pharma Incannex Healthcare Greenwich LifeSciences Citius Oncology (NASDAQ:CTOR) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Does the media favor CTOR or ALVR? In the previous week, Citius Oncology had 2 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Citius Oncology and 1 mentions for AlloVir. Citius Oncology's average media sentiment score of 0.31 beat AlloVir's score of 0.00 indicating that Citius Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AlloVir 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of CTOR or ALVR? 70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 6.7% of Citius Oncology shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate CTOR or ALVR? Citius Oncology currently has a consensus price target of $6.00, suggesting a potential upside of 252.94%. Given Citius Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Citius Oncology is more favorable than AlloVir.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, CTOR or ALVR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/AAlloVirN/AN/A-$190.42M-$20.23-0.24 Is CTOR or ALVR more profitable? Citius Oncology's return on equity of -51.93% beat AlloVir's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -51.93% -22.17% AlloVir N/A -71.03%-61.27% Which has more risk and volatility, CTOR or ALVR? Citius Oncology has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. SummaryCitius Oncology beats AlloVir on 9 of the 10 factors compared between the two stocks. Get AlloVir News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVR vs. The Competition Export to ExcelMetricAlloVirBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.01M$352.34M$6.04B$10.51BDividend YieldN/AN/A5.73%4.80%P/E Ratio-0.24N/A84.7027.24Price / SalesN/A490.63514.31200.41Price / CashN/A22.4437.5761.53Price / Book0.163.8112.316.74Net Income-$190.42M-$133.30M$3.32B$276.59M7 Day Performance-38.34%-3.97%-1.33%-0.47%1 Month Performance22.37%14.62%8.13%7.47%1 Year Performance-73.55%12.15%73.08%34.58% AlloVir Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVRAlloVirN/A$4.76+7.0%N/A-75.8%$24.01MN/A-0.24110High Trading VolumeCTORCitius Oncology3.0376 of 5 stars$1.91+2.4%$6.00+213.5%+61.9%$159.84MN/A0.00N/AGap UpPEPGPepGen3.4787 of 5 stars$4.85-2.2%$8.40+73.2%-47.6%$159.08MN/A-1.6430THTXTheratechnologiesN/A$3.42+0.9%N/A+174.3%$157.21M$84.38M-17.99140High Trading VolumeANROAlto Neuroscience2.5716 of 5 stars$5.78-11.7%$9.80+69.7%-59.7%$156.51MN/A-2.42N/ACGENCompugen1.3601 of 5 stars$1.74-3.1%$4.00+130.5%+25.6%$154.83M$27.86M-7.8970News CoverageCCCCC4 Therapeutics3.7595 of 5 stars$2.18-4.6%$8.50+290.8%-65.6%$154.80M$35.58M-1.38150ACOGAlpha Cognition2.9475 of 5 stars$7.40flat$20.00+170.3%N/A$154.66MN/A-4.63N/ANVCTNuvectis Pharma3.2461 of 5 stars$6.06+0.2%$15.33+153.0%-6.5%$154.29MN/A-5.188IXHLIncannex Healthcare0.8994 of 5 stars$0.44-1.0%N/A-76.8%$153.34M$90K-0.363Gap DownGLSIGreenwich LifeSciences1.2426 of 5 stars$11.21-0.7%$42.00+274.8%-23.7%$152.72MN/A-8.243Analyst Forecast Related Companies and Tools Related Companies CTOR Alternatives PEPG Alternatives THTX Alternatives ANRO Alternatives CGEN Alternatives CCCC Alternatives ACOG Alternatives NVCT Alternatives IXHL Alternatives GLSI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVR) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
